A Swedish listed biotechnology company
Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in clinical development stage, as well as our antibody platform CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).
Cantargia AB was founded in 2010 by the researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström with the goal to refine a discovery made by Professor Fioretos and Doctor Järås at Lund University. Their research had shown that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.
We develop treatments for life-threatening diseases
Cancer is a very complex disease and despite extensive research there is a great need for new treatments. Cancer continues to be one of the most common causes of death, and a disease that is associated with considerable suffering.
At Cantargia, we consider our work to be not only important and challenging, but also an opportunity to contribute to more effective and safe cancer treatments of the future. We apply our knowledge in the field of cancer research also to the development of products for other severe conditions, such as inflammatory and autoimmune diseases.
Cantargia’s vision is to develop a new generation of antibody-based treatments aimed at IL1RAP, with the potential to become an important part of future treatments for life-threatening diseases with better efficacy and safety.
A Swedish biotechnology company whose science is based on research from Lund University
Vision of becoming an important part in future treatments for life-threatening diseases
Experienced company management that has previously brought medicinal products to market
Noted on Nasdaq Stockholm’s main list (Small Cap)
Unique immunotherapy with a double mechanism of action
Highly relevant field of research with a clinically validated therapeutic mechanism
Scientific platform with many potential therapeutic areas
Robust patent portfolio